ABIONYX Pharma SA (EPA:ABNX)

France flag France · Delayed Price · Currency is EUR
1.300
-0.020 (-1.52%)
May 28, 2025, 5:35 PM CET
8.33%
Market Cap 45.08M
Revenue (ttm) 4.55M
Net Income (ttm) -4.38M
Shares Out 34.68M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 25,242
Average Volume 27,015
Open 1.332
Previous Close 1.320
Day's Range 1.300 - 1.332
52-Week Range 1.090 - 1.500
Beta 1.02
RSI 62.69
Earnings Date Sep 25, 2025

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 51
Stock Exchange Euronext Paris
Ticker Symbol ABNX
Full Company Profile

Financial Performance

In 2024, ABIONYX Pharma's revenue was 4.55 million, a decrease of -1.92% compared to the previous year's 4.64 million. Losses were -4.38 million, 24.5% more than in 2023.

Financial Statements

News

There is no news available yet.